Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EDP-323

Small molecule · developed by Enanta Pharmaceuticals

Phase 2 Most advanced trial (none active)

ENTA Developer

2 Registered trials

What is EDP-323?

EDP-323 is a drug studied in respiratory syncytial virus (RSV) infection and in drug-drug interaction assessment.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Infectious disease
Developer: Enanta Pharmaceuticals, Inc (ENTA)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06170242	Phase 2	RSV Infection	Completed	ENTA
NCT06917508	Phase 1	RSV Infection	Completed	ENTA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Drug Drug InteractionRSV Infection

More from Enanta Pharmaceuticals

EDP-235 Phase 2 EDP-297 Phase 1 EDP-305 Phase 2 EDP-322 Phase 1 EDP-494 Phase 1 EDP-514 Phase 1 EDP-721 Phase 1 EDP-788 Phase 1 EDP-978 Phase 1 EDP239 Phase 1 Zelicapavir Phase 2

Sources

ClinicalTrials.gov NCT06917508

Updated Oct 11, 2026. Something wrong or missing? Report it on the ENTA page.

Follow ENTA, the company behind EDP-323

See ENTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ENTA catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z